Starting from the findings of several observational studies showing a better outcome in CKD patients with higher Hb levels [6,7,8], and on the wave of the enthusiasm over these new anti-anemic drugs, it was hypothesized that aiming at high, near-to-normal Hb levels with ESA treatment would have significantly improved patient outcome. Here, GSTM1 is linked to chronic kidney disease.